Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
BCRX BioCryst Pharmaceuticals, Inc. daily Stock Chart
BCRX [NASD]
BioCryst Pharmaceuticals, Inc.
Healthcare | Biotechnology | USA
statements
Index- P/E- EPS (ttm)-1.21 Insider Own0.80% Shs Outstand153.54M Perf Week11.24%
Market Cap456.01M Forward P/E- EPS next Y-1.09 Insider Trans18.87% Shs Float152.74M Perf Month85.63%
Income-133.70M PEG- EPS next Q-0.26 Inst Own67.20% Short Float7.98% Perf Quarter-5.41%
Sales11.80M P/S38.65 EPS this Y-26.00% Inst Trans1.07% Short Ratio4.72 Perf Half Y-17.73%
Book/sh-0.37 P/B- EPS next Y10.70% ROA-107.80% Target Price7.13 Perf Year-65.42%
Cash/sh0.45 P/C6.67 EPS next 5Y19.90% ROE- 52W Range1.38 - 9.95 Perf YTD-63.20%
Dividend- P/FCF- EPS past 5Y-12.50% ROI-84.90% 52W High-70.15% Beta2.04
Dividend %- Quick Ratio0.90 Sales past 5Y3.60% Gross Margin86.50% 52W Low115.22% ATR0.24
Employees100 Current Ratio1.00 Sales Q/Q20.00% Oper. Margin- RSI (14)63.82 Volatility9.22% 11.03%
OptionableYes Debt/Eq- EPS Q/Q-21.30% Profit Margin- Rel Volume1.12 Prev Close2.96
ShortableYes LT Debt/Eq- EarningsNov 06 BMO Payout- Avg Volume2.58M Price2.97
Recom2.10 SMA2021.10% SMA5026.50% SMA200-31.71% Volume2,897,603 Change0.34%
Nov-15-19Upgrade BofA/Merrill Neutral → Buy $5 → $4
May-24-19Downgrade RBC Capital Mkts Outperform → Sector Perform $16 → $4.50
Nov-16-18Resumed Piper Jaffray Overweight $15
Aug-08-18Resumed JP Morgan Overweight $9
Jul-17-18Upgrade BofA/Merrill Underperform → Neutral
Jun-22-18Initiated Seaport Global Securities Neutral
Jan-02-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Dec-20-17Initiated Barclays Equal Weight $6
Sep-15-17Initiated RBC Capital Mkts Sector Perform $6
Sep-06-17Upgrade JP Morgan Neutral → Overweight
Sep-06-17Upgrade Jefferies Hold → Buy
Feb-16-17Initiated Ladenburg Thalmann Buy $11
Aug-12-16Upgrade Piper Jaffray Neutral → Overweight
Aug-04-16Downgrade JMP Securities Mkt Outperform → Mkt Perform
Feb-09-16Reiterated FBR Capital Outperform $18 → $6
Feb-09-16Downgrade Needham Buy → Hold
Feb-09-16Downgrade JP Morgan Overweight → Neutral
Feb-09-16Downgrade Jefferies Buy → Hold
Feb-08-16Downgrade Piper Jaffray Overweight → Neutral
Jan-06-16Upgrade Jefferies Hold → Buy
Dec-12-19 02:34PM  BioCryst Submits NDA for Hereditary Angioedema Candidate Zacks +7.25%
Dec-11-19 03:04PM  BioCryst seeks federal approval for its lead drug candidate American City Business Journals
12:16PM  Here is What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. (BCRX) Insider Monkey
07:00AM  BioCryst Submits New Drug Application for Oral, Once Daily Berotralstat (BCX7353) to Prevent HAE Attacks GlobeNewswire
Dec-04-19 10:02AM  Implied Volatility Surging for BioCryst (BCRX) Stock Options Zacks
07:00AM  BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-21-19 07:49AM  Edited Transcript of BCRX earnings conference call or presentation 6-Nov-19 1:00pm GMT Thomson Reuters StreetEvents +6.16%
Nov-20-19 02:18PM  BioCryst locks down another $20M on heels of public offering American City Business Journals
Nov-18-19 04:01PM  BioCryst Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Completion of Public Offering of Common Stock GlobeNewswire
Nov-15-19 01:38PM  Bank Of America Upgrades BioCryst As Financing Overhang Lifts Partially Benzinga +10.41%
10:09AM  The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval Benzinga
Nov-14-19 04:01PM  BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
02:28PM  Durham company sets stage for $55 million offering American City Business Journals
Nov-13-19 07:10PM  BioCryst Prices Public Offering of Common Stock GlobeNewswire -10.61%
Nov-12-19 04:01PM  BioCryst Commences Public Offering of Common Stock GlobeNewswire -6.28%
Nov-11-19 07:45AM  Imagine Owning BioCryst Pharmaceuticals (NASDAQ:BCRX) And Trying To Stomach The 80% Share Price Drop Simply Wall St. -5.91%
Nov-07-19 07:00AM  Biocryst to Present Abstracts at Annual Scientific Meeting of American College of Allergy, Asthma & Immunology GlobeNewswire
Nov-06-19 08:25AM  BioCryst Pharmaceuticals (BCRX) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:36AM  Triangle pharma inks $44M Japanese deal for new drug American City Business Journals
07:00AM  BioCryst Reports Third Quarter 2019 Financial Results and Upcoming Key Milestones GlobeNewswire
06:55AM  New Clinical Trial Results and Market Research Support Significant Commercial Opportunity for Oral, Once Daily BCX7353 in HAE GlobeNewswire
Nov-05-19 06:53AM  The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment Benzinga -6.02%
01:05AM  BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks GlobeNewswire
Nov-04-19 07:00AM  BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire
Nov-01-19 10:03AM  Baker Brothers Make $1.4 Billion in Two Weeks on Biotech Bloomberg
07:00AM  BioCryst Begins Phase 1 Trial With BCX9250, an Oral ALK-2 Inhibitor, for Treatment of Fibrodysplasia Ossificans Progressiva GlobeNewswire
Oct-31-19 01:51PM  BioCryst Pharmaceuticals, Inc. (BCRX) Are Selling These Hedge Funds Insider Monkey
Oct-30-19 10:33AM  Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for Zacks -8.48%
Oct-29-19 10:32AM  Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for Zacks -5.74%
07:00AM  BioCryst to Provide Commercial Update and Report Third Quarter 2019 Financial Results on November 6 GlobeNewswire
Oct-28-19 06:59AM  BioCryst Reports Data From Phase 1 Trial of BCX9930 and Announces Plans to Advance Program Into Proof of Concept Study in PNH Patients GlobeNewswire
Oct-03-19 07:00AM  BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-26-19 02:41PM  Triangle drugmaker lands $14M purchase from federal government for flu treatment American City Business Journals
07:15AM  U.S. Government Exercises Option for Additonal Rapivab® for Strategic National Stockpile GlobeNewswire
Sep-24-19 04:15PM  BioCryst Pharmaceuticals to Present at Cantor Global Healthcare Conference GlobeNewswire
Sep-23-19 07:00AM  BioCryst Appoints Helen Thackray, M.D., to Board of Directors GlobeNewswire +12.94%
Sep-10-19 07:44AM  Triangle drugmaker looks to rebound with estimated $2 billion global market for new drug American City Business Journals +5.71%
Sep-04-19 07:00AM  BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Sep-03-19 04:15PM  BioCryst to Present at H.C. Wainwright Global Investment Conference GlobeNewswire
Aug-13-19 01:27PM  Edited Transcript of BCRX earnings conference call or presentation 6-Aug-19 12:30pm GMT Thomson Reuters StreetEvents +6.79%
Aug-06-19 05:23PM  Biocryst Pharmaceuticals Inc (BCRX) Q2 2019 Earnings Call Transcript Motley Fool
09:45AM  BioCryst Pharmaceuticals (BCRX) Reports Q2 Loss, Lags Revenue Estimates Zacks
07:15AM  BioCryst Reports Second Quarter 2019 Financial Results GlobeNewswire
Aug-05-19 07:15AM  BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(C)(4) GlobeNewswire -7.19%
Jul-30-19 10:38AM  Earnings Preview: BioCryst Pharmaceuticals (BCRX) Q2 Earnings Expected to Decline Zacks
Jul-23-19 07:15AM  BioCryst to Report Second Quarter 2019 Financial Results on August 6 GlobeNewswire
Jul-03-19 07:15AM  BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
Jul-01-19 07:15AM  BioCryst Appoints Megan Sniecinski Chief Business Officer GlobeNewswire
Jun-27-19 04:15PM  Biocryst Begins Enrollment of Phase 1 Trial of BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases GlobeNewswire
Jun-11-19 08:20PM  Is BioCryst Pharmaceuticals, Inc. (BCRX) A Good Stock To Buy? Insider Monkey -5.54%
Jun-05-19 11:25AM  Edited Transcript of BCRX earnings conference call or presentation 8-May-19 12:30pm GMT Thomson Reuters StreetEvents
Jun-04-19 04:15PM  BioCryst Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) GlobeNewswire
May-31-19 07:00AM  BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
May-30-19 02:03PM  Here's Why BioCryst Pharmaceuticals Is Soaring Today Motley Fool +15.46%
May-22-19 07:34AM  The Daily Biotech Pulse: Tocagen Tumbles, OncoSec Offering, Novartis Asthma Combo Drug Study Benzinga
May-21-19 04:40PM  Why J.C. Penney, Mallinckrodt, and BioCryst Pharmaceuticals Slumped Today Motley Fool -52.91%
02:30PM  In less than six hours today, this Durham company's stock has dropped 50 percent American City Business Journals
01:18PM  Here's Why BioCryst Pharmaceuticals Collapsed Today Motley Fool
10:54AM  BioCryst Trades Sharply Lower Despite Acing Late-Stage Hereditary Angioedema Drug Trial Benzinga
07:00AM  BioCrysts Oral BCX7353 Meets Primary Endpoint in Phase 3 APeX-2 Trial GlobeNewswire
May-14-19 08:46AM  Do Options Traders Know Something About BioCryst Pharmaceuticals (BCRX) Stock We Don't? Zacks
May-10-19 07:00AM  BioCryst to Present at Bank of America Merrill Lynch Health Care Conference GlobeNewswire
May-09-19 04:15PM  BioCryst Completes Phase 1 Clinical Trial of Galidesivir GlobeNewswire
May-08-19 02:23PM  Biocryst Pharmaceuticals Inc (BCRX) Q1 2019 Earnings Call Transcript Motley Fool
09:05AM  BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates Zacks
07:59AM  BioCryst: 1Q Earnings Snapshot Associated Press
07:00AM  BioCryst Reports First Quarter 2019 Financial Results GlobeNewswire
May-06-19 07:00AM  BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire +5.05%
May-03-19 10:35AM  Heres What Hedge Funds Think About BioCryst Pharmaceuticals, Inc. (BCRX) Insider Monkey
May-01-19 10:33AM  Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for Zacks
Apr-24-19 07:00AM  BioCryst to Report First Quarter 2019 Financial Results on May 8 GlobeNewswire
Apr-04-19 09:36AM  Implied Volatility Surging for BioCryst Pharmaceuticals (BCRX) Stock Options Zacks
Apr-01-19 07:00AM  BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
Mar-25-19 02:10PM  BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX): What Can We Expect From This High Growth Stock? Simply Wall St.
Mar-08-19 04:40PM  Edited Transcript of BCRX earnings conference call or presentation 4-Mar-19 1:30pm GMT Thomson Reuters StreetEvents
Mar-06-19 08:20AM  Report: Developing Opportunities within Sarepta Therapeutics, Sally Beauty, Danaher, Ellie Mae, BioCryst Pharmaceuticals, and Akcea Therapeutics Future Expectations, Projections Moving into 2019 GlobeNewswire
Mar-04-19 11:29AM  Biocryst Pharmaceuticals Inc (BCRX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:02AM  BioCryst Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
07:00AM  BioCryst Advancing BCX9930, an Oral Factor D Inhibitor for Complement-Mediated Diseases, into Phase 1 Development GlobeNewswire
Mar-03-19 09:41AM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings, IPOs Benzinga
Feb-28-19 07:00AM  BioCryst to Present at Barclays Global Healthcare Conference GlobeNewswire
Feb-25-19 10:30AM  Analysts Estimate BioCryst Pharmaceuticals (BCRX) to Report a Decline in Earnings: What to Look Out for Zacks -5.33%
Feb-23-19 12:45PM  BioCryst Reports ZENITH-1 Results With Oral BCX7353 Which Confirm Rapid Onset of Action, Sustained Activity and Robust Dose Response for Treatment of Acute HAE Attacks GlobeNewswire
Feb-18-19 07:00AM  BioCryst to Report Fourth Quarter and Full Year 2018 Financial Results on March 4 GlobeNewswire
Feb-15-19 02:00PM  The Week Ahead In Biotech: Conferences, Clinical Trials And Earnings Benzinga
Feb-14-19 03:30PM  Here Are 5 Biotech Stocks To Love This Valentine's Day: Analyst Investor's Business Daily
Feb-12-19 07:20AM  Detailed Research: Economic Perspectives on Callon Petroleum, Summit Materials, Echo Global Logistics, BioCryst Pharmaceuticals, NEXEO SOLUTIONS, and NL Industries What Drives Growth in Today's Competitive Landscape GlobeNewswire
Feb-06-19 03:10PM  How CEO Stonehouse is building up BioCryst's war chest to finance trials, drug launch American City Business Journals
07:00AM  BioCryst Strengthens Cash Position With Flexible $100 Million Debt Facility GlobeNewswire
Feb-05-19 07:00AM  BioCryst to Present ZENITH-1 Results at American Academy of Allergy, Asthma & Immunology Annual Meeting GlobeNewswire +6.21%
Jan-04-19 07:00AM  BioCryst Appoints Steve Aselage to Board of Directors GlobeNewswire +5.51%
Jan-02-19 07:00AM  BioCryst to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +5.33%
07:00AM  BioCryst Initiates Phase 1 Clinical Trial of Galidesivir GlobeNewswire
Dec-27-18 09:23AM  Stocks down in December for pharma firms in the Triangle American City Business Journals
Dec-17-18 06:42PM  Edited Transcript of BCRX earnings conference call or presentation 6-Nov-18 1:30pm GMT Thomson Reuters StreetEvents
Dec-16-18 09:13AM  BioCryst Pharmaceuticals, Inc. (BCRX) Hedge Funds Are Snapping Up Insider Monkey
Nov-27-18 08:55AM  New Research Coverage Highlights Immunomedics, Surmodics, PDF Solutions, Stepan, Express Scripts Holding, and BioCryst Pharmaceuticals Consolidated Revenues, Company Growth, and Expectations for 2018 GlobeNewswire
Nov-20-18 07:00AM  BioCryst Appoints Rare Disease Expert Theresa Heggie to Board of Directors GlobeNewswire +5.97%
Nov-16-18 07:00AM  BioCryst Presents Data Highlighting the Rapid and Sustained Plasma Concentrations of BCX7353 in HAE Patients at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology GlobeNewswire +7.66%
Nov-08-18 07:00AM  BioCryst to Present at Upcoming Investor Conferences GlobeNewswire
BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma. It is also developing BCX7353, an oral serine protease inhibitor and oral dose formulation that is in Phase III clinical trials to treat hereditary angioedema; BCX9930, an oral factor D inhibitor, which is in Phase I clinical trials for mediated diseases; BCX9250, an oral activin receptor-like kinase-2 inhibitors that is in preclinical trials to treat fibrodysplasia ossificans progressive; and Galidesivir, an RNA dependent-RNA polymerase inhibitor, which is in Phase I clinical trials to treat various RNA viruses, including Marburg, Yellow Fever, Ebola, and Zika. The company has collaborations and in-license relationships with U.S. Department of Health and Human Services; National Institute of Allergy and Infectious Diseases; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; Mundipharma International Holdings Limited; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Stonehouse Jon PPresident & CEONov 18Buy1.4550,00072,500778,086Nov 18 04:17 PM
Sniecinski MeganChief Business OfficerNov 18Buy1.4545,00065,25045,000Nov 18 04:16 PM
LEE KENNETH B JRDirectorNov 18Buy1.455,0007,25015,252Nov 18 04:14 PM
INGRAM ROBERT ALEXANDERDirectorNov 18Buy1.4520,00029,00048,088Nov 18 04:12 PM
Hutson Nancy JDirectorNov 18Buy1.4510,00014,50053,046Nov 18 04:10 PM
HEGGIE THERESADirectorNov 18Buy1.455,0007,2506,672Nov 18 04:08 PM
Barnes Alane PSenior VP, Chief Legal OfficerNov 18Buy1.4520,00029,000102,061Nov 18 04:05 PM
Babu Yarlagadda SSenior VP - Drug DiscoveryNov 18Buy1.4525,00036,250155,587Nov 18 04:03 PM
ASELAGE STEVEDirectorNov 18Buy1.4515,00021,75021,672Nov 18 04:01 PM
ASELAGE STEVEDirectorMay 22Buy3.573,00010,7105,000May 24 04:20 PM
STAAB THOMAS R IISenior Vice President and CFOMay 17Sale7.452,50018,625125,176May 20 04:21 PM
STAAB THOMAS R IISenior Vice President and CFOMay 16Option Exercise1.424,7506,745134,926May 20 04:21 PM
STAAB THOMAS R IISenior Vice President and CFOMay 16Sale7.727,25055,970127,676May 20 04:21 PM
STAAB THOMAS R IISenior Vice President and CFOMay 15Option Exercise1.424,7506,745137,426May 16 04:29 PM
STAAB THOMAS R IISenior Vice President and CFOMay 15Sale7.927,25057,420130,176May 16 04:29 PM
STAAB THOMAS R IISenior Vice President and CFOMay 14Option Exercise1.424,5006,390137,176May 16 04:29 PM
STAAB THOMAS R IISenior Vice President and CFOMay 14Sale7.624,50034,290132,676May 16 04:29 PM
STAAB THOMAS R IISenior Vice President and CFOMay 13Option Exercise5.519,75053,723142,426May 13 04:57 PM
STAAB THOMAS R IISenior Vice President and CFOMay 13Sale7.769,75075,660132,676May 13 04:57 PM
STAAB THOMAS R IISenior Vice President and CFOMay 09Option Exercise5.519,75053,723142,426May 13 04:57 PM
STAAB THOMAS R IISenior Vice President and CFOMay 09Sale7.639,75074,393132,676May 13 04:57 PM
STAAB THOMAS R IISenior Vice President and CFOMay 06Option Exercise5.519,00049,590141,676May 06 04:51 PM
STAAB THOMAS R IISenior Vice President and CFOMay 06Sale7.759,00069,750132,676May 06 04:51 PM
STAAB THOMAS R IISenior Vice President and CFOMay 02Option Exercise5.517,75042,703140,426May 06 04:51 PM
STAAB THOMAS R IISenior Vice President and CFOMay 02Sale7.307,75056,575132,676May 06 04:51 PM
STAAB THOMAS R IISenior Vice President and CFOApr 04Option Exercise5.517,50041,325140,176Apr 08 02:30 PM
STAAB THOMAS R IISenior Vice President and CFOApr 04Sale8.817,50066,075132,676Apr 08 02:30 PM
ASELAGE STEVEDirectorMar 12Buy8.302,00016,6002,000Mar 14 04:18 PM
STAAB THOMAS R IISenior Vice President and CFOJan 28Option Exercise5.455,00027,250133,426Jan 30 04:10 PM
Powell LynneSenior VP - CCOJan 28Option Exercise3.226,00019,3204,000Jan 29 04:21 PM
Powell LynneSenior VP - CCOJan 28Sale9.896,00059,3400Jan 29 04:21 PM
STAAB THOMAS R IISenior Vice President and CFOJan 28Sale9.855,00049,250128,426Jan 30 04:10 PM
Powell LynneSenior VP - CCOJan 25Option Exercise3.226,00019,3206,000Jan 29 04:21 PM
Powell LynneSenior VP - CCOJan 25Sale9.606,00057,6000Jan 29 04:21 PM
Powell LynneSenior VP - CCOJan 18Option Exercise3.222,0006,4402,000Jan 23 04:12 PM
Powell LynneSenior VP - CCOJan 18Sale9.402,00018,8000Jan 23 04:12 PM
Powell LynneSenior VP - CCOJan 16Option Exercise3.223,0469,8083,046Jan 18 04:03 PM
Powell LynneSenior VP - CCOJan 16Sale9.273,04628,2360Jan 18 04:03 PM
Powell LynneSenior VP - CCOJan 14Option Exercise3.229543,072954Jan 16 04:24 PM
Powell LynneSenior VP - CCOJan 14Sale9.209548,7770Jan 16 04:24 PM
Sheridan William PSenior VP - CMODec 18Sale7.5820,488155,2992,725Dec 20 04:37 PM
open in yahoo | open in reuters | open in google